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SBRT) despite many differences to GN-RF: (1) safety margins 
are used in almost all SBRT indications; (2) in lung SBRT, the 
use of safety margins will result in inclusion of low density 
lung tissue into the target volume; (3) radiotherapy delivery 
is today performed using MLC and in many centers intensity-
modulated techniques allowing more sophisticated dose 
shaping; (4) target and organs at risk motion will affect the 
delivered dose profile as compared the planned dose profile; 
(5) the composition of the taget volumes in SBRT is very 
different to GN-RS - Organs-at-risk are not only close by but 
within the target volume; (6) in the RTOG protocols of SBRT 
for stage I NSCLC, dose prescription to a wide range of 
isodose lines is allowed.  
Based on these differences between GN-RS and SBRT above, 
it is obvious that the concept of dose prescription to a fixed 
isodose line is not sufficient for SBRT practice. The dose 
profile within the target volume needs to be sufficiently 
prescribed and reported to achieve better standardization 
and comparability between institutions, studies and 
individual patients. Additionally, current SBRT technology 
allows to adapt the dose profile within the PTV to the 
patient-specific clinical requirements: homogeneous dose 
profiles or even cold spots might allow organ at risk sparing; 
in contrast, an escalation of the dose within the target 
center might be beneficial for targets without critical normal 
tissue within the PTV. Recommendations by the ICRU specific 
for the needs of SBRT are eagerly awaited and future studies 
will better define how to optimize SBRT dose planning. 
 
SP-0413  
To use or not to use the LQ model at "high" radiation doses 
W. Dörr
1Medical University of Vienna, Dept. of Radiation Oncology, 
Vienna, Austria 
1 
 
In curative SBRT regimen, few large doses per fraction are 
applied in a highly conformal way. Such protocols, however, 
usually do not only differ from conventional protocols in the 
size of the dose per fraction, but also with regard to overall 
treatment time and total (equieffective) dose. Moreover, 
large doses per fraction are usually administered to (normal 
tissue) volumes that are clearly smaller compared to 
conventional protocols. Hence, all these parameters, i.e. 
recovery, repopulation, tumour reoxygenation and normal 
tissue volume effects, need to be included into 
considerations concerning the biological effect of SBRT 
protocols – independently for tumor, early and late 
responding tissues.  
The effect of dose per fraction (“recovery”) for tumors is – 
with few exceptions – considered as low, as expressed by a 
high a/b-value in the linear-quadratic (LQ) model. Recently, 
a high fractionation effect was shown for prostate and breast 
tumors, and is also discussed for others. For lung tumours, 
however, a small capacity for recovery can be assumed. Early 
responding normal tissues usually display a similarly low 
fractionation effect, while most late radiation effects have a 
high sensitivity with regard to changes in dose per fraction. 
Hence, doses per fraction must be adjusted to the respective 
tumor type and the expected (late) morbidity pattern in 
order to achieve the biologically equieffective doses that 
result in optimum dissociation between treatment efficacy 
and adverse events.  
The linear-quadratic model has been shown to only 
inadequately describe the effect of large doses per fraction 
(>6-10 Gy) for cell survival endpoints in vitro (colony forming 
assay) and in vivo (e.g. intestinal crypt survival assay). Here, 
the LQ model overestimates the effects of exposure in the 
high-dose region. It needs to be emphasized, however, that 
in the vast majority of pre-clinical investigations and analyses 
of the fractionation effect for morphological and functional 
endpoints, large doses per fraction and/or single doses were 
regularly included. In clear contrast to the cell survival based 
analyses, these studies in general do not show any major 
difference of the fit of the LQ model for the in- or exclusion 
of large doses per fraction in the analyses. Moreover, no 
deviation of the resulting a/b-values from the respective 
estimates from clinical data was observed. This indicates the 
applicability of the LQ model also for the calculation of 
equieffective doses at high doses per fraction, such as 
applied in SBRT protocols in the lung. Besides high dose per 
fraction,  
SBRT protocols regularly include a shortening of the overall 
treatment time (OTT) compared to conventional or 
moderately hypofractionated protocols. This is associated 
with less tumour repopulation, which also contributes to the 
increased tumor effectiveness. With very few fractions in 
short time intervals, however, tumour reoxygenation may 
also be less effective, thus at least partly counteracting the 
benefit of the shorter OTT. It also needs to be noted that 
SBRT protocols with short OTT are less permissive for 
regenerative processes in early responding normal tissues. 
These protocols hence also bear a risk of increased early 
normal tissue reactions and thus, in certain tissues, of 
enhanced (“consequential”) late effects.  
The administration of large doses per fraction and large total 
doses is mainly facilitated by a strong conformation of the 
high-dose volume to the target, i. e. a minimization of the 
normal tissue volumes exposed to these doses, and is 
associated with very steep dose gradients within the adjacent 
normal tissues. However, it must be emphasized that in such 
scenarios, not only the amount of normal tissue effects may 
be changed, but also their quality, with altered tissue 
pathophysiology and morbidity endpoints that are usually not 
observed with conventional or moderately hypofractionated 
protocols. Prominent examples are the manifestation of 
atrophic rather than fibrotic processes, or pathologic rib 
fractures in SBRT of peripheral lung tumors.  
In conclusion, administration of large doses per fraction in 
SBRT may be advantageous for biological reasons. Estimation 
of biologically equieffective doses may be based on the 
standard LQ model. However, such treatment strategies not 
only impact on tissue recovery, but can also affect other 
radiobiological parameters (radiopathology, repopulation, 
volume effects) in a complex manner. Therefore, the 
patients included in such therapeutic protocols need to be 
monitored carefully not only for treatment outcome, but also 
for treatment-related morbidity. 
 
Proffered Papers: Physics 10: Functional Imaging I  
 
 
OC-0414  
Assessing 4DCT-ventilation as a functional imaging modality 
for thoracic radiation therapy 
Y. Vinogradskiy
1University of Colorado Denver, Radiation Oncology, Aurora- 
CO, USA 
1, L. Schubert1, T. Waxweiler1, Q. Diot1, R. 
Castillo2, E. Castillo3, T. Guerrero3, C. Rusthoven1, L.E. 
Gaspar1, B. Kavanagh1, M. Miften1 
2University of Texas Medical Branch, Radiation Oncology, 
Galveston, USA 
3Beaumont Health System, Radiation Oncology, Royal Oak, 
USA 
 
Purpose or Objective: 4DCT-ventilation is an exciting new 
lung function imaging modality that uses 4DCT data to 
calculate lung function maps (Fig 1).  
 
 
